A Phase 1 interventional study of Atorvastatin and Metformin in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Researchers want to learn about ulonivirine when given with atorvastatin and metformin in healthy people. The goal of this study is to compare the amount of atorvastatin and metformin in a person's body over time when given with and without ulonivirine.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Period 1, participants will receive atorvastatin and metformin. In Period 2, participants will receive atorvastatin, metformin, and ulonivirine.
Drug: Atorvastatin · Drug: Metformin · Drug: Ulonivirine
Oral tablet
Oral tablet
Oral tablet
Also known as: MK-8507
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Atorvastatin
Blood samples will be collected at multiple time points to determine the AUC0-inf of atorvastatin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
AUC0-inf of Metformin
Blood samples will be collected at multiple time points to determine the AUC0-inf of metformin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
Area Under the Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of Atorvastatin
Blood samples will be collected at multiple time points to determine the AUC0-last of atorvastatin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
Maximum Plasma Concentration (Cmax) of Atorvastatin
Blood samples will be collected at multiple time points to determine the Cmax of atorvastatin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
Plasma Concentration at 24 Hours (C24) of Atorvastatin
Blood samples will be collected to estimate the C24 of atorvastatin
Time frame: 24 hours post-dose
Time to Maximum Plasma Concentration (Tmax) of Atorvastatin
Blood samples will be collected at multiple time points to estimate the Tmax of atorvastatin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
Apparent Terminal Half-life (t1/2) of Atorvastatin
Blood samples will be collected at multiple time points to estimate the t1/2 of atorvastatin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
AUC0-last of Atorvastatin Metabolite (2-OH Atorvastatin)
Blood samples will be collected at multiple time points to determine the AUC0-last of 2-OH atorvastatin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
AUC0-inf of 2-OH Atorvastatin
Blood samples will be collected at multiple time points to determine the AUC0-inf of 2-OH atorvastatin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
Cmax of 2-OH Atorvastatin
Blood samples will be collected at multiple time points to determine the Cmax of 2-OH atorvastatin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
C24 of 2-OH Atorvastatin
Blood samples will be collected to estimate the C24 of 2-OH atorvastatin
Time frame: 24 hours post-dose
Tmax of 2-OH Atorvastatin
Blood samples will be collected at multiple time points to estimate the Tmax of 2-OH atorvastatin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
t1/2 of 2-OH Atorvastatin
Blood samples will be collected at multiple time points to estimate the t1/2 of 2-OH atorvastatin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
AUC0-last of Atorvastatin Metabolite (4-OH Atorvastatin)
Blood samples will be collected at multiple time points to determine the AUC0-last of 4-OH atorvastatin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
AUC0-inf of 4-OH Atorvastatin
Blood samples will be collected at multiple time points to determine the AUC0-inf of 4-OH atorvastatin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
Cmax of 4-OH Atorvastatin
Blood samples will be collected at multiple time points to determine the Cmax of 4-OH atorvastatin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
C24 of 4-OH Atorvastatin
Blood samples will be collected to estimate the C24 of 4-OH atorvastatin
Time frame: 24 hours post-dose
Tmax of 4-OH Atorvastatin
Blood samples will be collected at multiple time points to estimate the Tmax of 4-OH atorvastatin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
t1/2 of 4-OH Atorvastatin
Blood samples will be collected at multiple time points to estimate the t1/2 of 4-OH atorvastatin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
AUC0-last of Metformin
Blood samples will be collected at multiple time points to determine the AUC0-last of metformin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
Cmax of Metformin
Blood samples will be collected at multiple time points to determine the Cmax of metformin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
C24 of Metformin
Blood samples will be collected to estimate the C24 of metformin
Time frame: 24 hours post-dose
Tmax of Metformin
Blood samples will be collected at multiple time points to estimate the Tmax of metformin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
t1/2 of Metformin
Blood samples will be collected at multiple time points to estimate the t1/2 of metformin
Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose
Number of Participants Who Experience One or More Adverse Events (AEs)
An AE is any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 21 days after first dose
Number of Participants Who Discontinue Study Intervention Due to an AE
An AE is any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 7 days after first dose
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Apr 2026 to primary completion in May 2026, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atorvastatin · Metformin · Ulonivirine